Related Experiment Videos
Gene silencing--a new theory of aging
1Burzynski Clinic, Houston, TX 77055, USA. info@burzynskiclinic.com
Abstract:
The aging process involves silencing of the genes through methylation of promoter sequences and the acetylation of histones. This process contributes not only to aging, but also cancer when silencing affects tumor suppressor genes. Antineoplastons work as molecular switches, turning inactive tumor suppressor genes back on through demethylation of the DNA and acetylation of the histones. While they activate tumor suppressor genes, antineoplastons also activate some additional genes silenced during the aging process. Evidence of activation of silenced genes can be pursued by documenting the relationship between 'molecular switches' - DNA-demethylating agents and histone deacetylation inhibitors, genes which are turned on by them, and clinical anti-aging changes.
Insights
Antineoplastons act as molecular switches, reactivating silenced tumor suppressor genes through DNA demethylation and histone acetylation. This process shows potential for anti-aging and cancer therapy by reversing gene silencing.
Area of Science:
- Epigenetics
- Molecular Biology
- Oncology
Background:
- Aging is associated with gene silencing via DNA methylation and histone acetylation.
- Silencing of tumor suppressor genes contributes to aging and cancer development.
- Antineoplastons are proposed to reverse these epigenetic changes.
Purpose of the Study:
- To investigate the role of antineoplastons as molecular switches.
- To explore the potential of antineoplastons in reversing age-related gene silencing.
- To examine the link between antineoplastons, gene activation, and anti-aging effects.
Main Methods:
- Investigating antineoplastons' mechanism of action as DNA demethylating agents and histone deacetylation inhibitors.
- Documenting gene activation by antineoplastons.
- Correlating gene activation with clinical anti-aging changes.
Main Results:
- Antineoplastons activate silenced tumor suppressor genes.
- Antineoplastons also activate other genes silenced during aging.
- Evidence supports antineoplastons' role as molecular switches reversing epigenetic silencing.
Conclusions:
- Antineoplastons can reverse epigenetic silencing associated with aging and cancer.
- Further research can explore the therapeutic potential of antineoplastons for anti-aging and oncology.
- Documenting the relationship between molecular switches, gene activation, and clinical outcomes is crucial.